Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination | CDT Stock News Conduit Pharmaceuticals Limited (“Conduit Pharmaceuticals”), a multi-asset clinical-stage disease-agnostic life science
Murphy Canyon Acquisition Corp. Announces Stockholder Approval of the Proposed Combination with Conduit Pharmaceuticals Limited SAN DIEGO, CA / ACCESSWIRE / September 20, 2023 / Murphy Canyon Acquisition Corp. (Nasdaq:MURF) ("MURF" or "Murphy Canyon"), a special purpose acquisition company, announced today that at a special meeting of the MURF stockholders (the "Special …
Murphy Canyon Acquisition Corp. Announces Postponement of its Special Meeting of Stockholders for Approving its Initial Business Combination with Conduit SAN DIEGO, CA / ACCESSWIRE / August 31, 2023 / Murphy Canyon Acquisition Corp. (Nasdaq:"MURF" or "Murphy Canyon") announced today that its special meeting of stockholders (the "Meeting"), which was originally scheduled for September 7, 2023, has …
SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Murphy Canyon Acquisition Corp. with Conduit Pharmaceuticals Limited Special meeting of Murphy Canyon stockholders to vote on the proposed business combination scheduled for September 7, 2023 Conduit is a disease agnostic life science company providing an efficient model for compound development led by a highly experienced team of pharmaceutical executives Murphy Canyon and Conduit entered into a definitive business combination agreement dated November 8, 2022, as amended (the "Business Combination Agreement") Combined company expected to be named Conduit Pharmaceuticals Inc. and listed on Nasdaq in the third quarter of 2023 under the symbols "CDT" and "CDTTW" SAN DIEGO, CA / ACCESSWIRE / August 16, 2023 / Murphy Canyon Acquisition Corp. (NASDAQ:MURF) or ("Murphy Canyon"), a blank-check special purpose acquisition company, is pleased to announce that its proxy statement/registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC") on May 12, 2023, as amended (the "Registration Statement"), was declared effective by the SEC on August 11, 2023.
U.S. IPO Weekly Recap: The February IPO Market Kicks Off With 2 Biotechs U.S. IPO Weekly Recap: The February IPO Market Kicks Off With 2 Biotechs